What is the current Price Target for the Qualigen Therapeutics Inc stock?

The average Qualigen Therapeutics Inc target price is $5.10. This is 78.95% higher than the current stock price. The highest price target is 84.21%, the lowest is 77.19%. 3 Analysts have issued a price target Qualigen Therapeutics Inc 2026 .

How high will the Qualigen Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Qualigen Therapeutics Inc stock will rise. The performance of stocks, including the Qualigen Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Qualigen Therapeutics Inc stock today?

The performance of Qualigen Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Qualigen Therapeutics Inc stock fall?

The decline in Qualigen Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Qualigen Therapeutics Inc Forecast, price target & analysts

$2.85

6.56% today

Nasdaq, Oct 31, 09:00 pm CET

ISIN

US74754R1032

Symbol

QLGN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Qualigen Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Qualigen Therapeutics Inc Classifications & Recommendation:

Buy

86%

Hold

14%

Qualigen Therapeutics Inc Price Target

Target Price	$5.10
Price	$2.85
Potential	78.95% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target Qualigen Therapeutics Inc 2026 . The average Qualigen Therapeutics Inc target price is $5.10. This is 78.95% register free of charge higher than the current stock price. The highest price target is $5.25 84.21% register free of charge , the lowest is $5.05 77.19% register free of charge .
	A rating was issued by 7 analysts: 6 Analysts recommend Qualigen Therapeutics Inc to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Qualigen Therapeutics Inc stock has an average upside potential 2026 of 78.95% register free of charge . Most analysts recommend the Qualigen Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
P/E		negative

3 Analysts have issued a Qualigen Therapeutics Inc forecast for earnings per share. The average Qualigen Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

Current	-0.73	147.04%
2025	-4.21 474.20% Unlock

Qualigen Therapeutics Inc...

Discover more stocks with a high price target

TUI 51.99%

Adidas 48.21%

Deutsche Telekom 44.14%

Novo Nordisk 42.05%

Meta Platforms (Facebook) 36.95%

BYD 35.21%

BioNTech SE - ADR 34.48%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now